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An MR contrast agent targeted to the GRP receptor will be a novel pharmaceutical capable of non-invasively, and at high spatial resolution, characterizing healthy and patholological regions within the prostate. The goal of the research is to develop a magnetic nanoparticle MR contrast targeted to the gastrin releasing peptide receptor (GRP receptor) that will be used to image the intra-prostatic distribution of this key molecular marker. Because of technical problems in imaging the GRP receptor in animal models of prostate cancer, we have been imaging the expression of this receptor in the normal mouse pancreas. Our long term goal is to use this animal model to refine our understanding of the interaction of magnetic nanoparticles with this receptor and return to the animal prostate cancer models. An MR contrast agent targeted to the GRP receptor will be a novel pharmaceutical capable of non-invasively, and at high spatial resolution, characterizing healthy and patholological regions within the prostate. The goal of the research is to develop a magnetic nanoparticle MR contrast targeted to the gastrin releasing peptide receptor (GRP receptor) that will be used to image the intra-prostatic distribution of this key molecular marker.
Because of technical problems in imaging the GRP receptor in animal models of prostate cancer, we have been imaging the expression of this receptor in the normal mouse pancreas. Our long term goal is to use this animal model to refine our understanding of the interaction of magnetic nanoparticles with this receptor and return to the animal prostate cancer models.
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Results and Discussion (Body)
The third year of our work plan was initiated and will be completed in the extension of time requested. The original goal was to image the expression of the GRP receptor using in an animal model of prostate cancer. We have initiated imaging studies with the bombesin peptide-nanoparticle conjugate developed during years 1 and 2 of the current research by imaging the receptor in a convenient animal model, the normal mouse. The GRP receptor is expressed at high levels in the normal rodent pancreas.
I. Synthesis of peptide-nanoparticle conjugates
Based on earlier studies optimizing the peptide and peptide nanoparticle, we have use the bombesin-like peptide below in the current studies along with succinimidyl acetic acid as a conjugating reagent. Bombesin-like peptide = FITC-bACdddGQRLGNQTAVGHLM, where b= beta alanine.
II. Preliminary studies imaging the of GRP receptor in normal mouse pancreas by fluorescence reflectance imaging.
We have employed fluorescence reflectance of imaging of dissected tissues to examine the 
